Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.
about
Breast cancer brain metastases: the last frontierHuman epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic optionsEmerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancerCurrent approaches to the treatment of metastatic brain tumours.Progress in the biological understanding and management of breast cancer-associated central nervous system metastases.Central nervous system cancersRelationship between HER-2 overexpression and brain metastasis in esophageal cancer patients.Systemic treatment after whole-brain radiotherapy may improve survival in RPA class II/III breast cancer patients with brain metastasis.Efficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine: results from 51 Japanese patients treated in a clinical study.Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier.Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases.Unsanctifying the sanctuary: challenges and opportunities with brain metastases.Efficacy and tolerability of lapatinib in the management of breast cancerPreclinical approaches to study the biology and treatment of brain metastases.Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival.Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer.Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA.HER-2 Expression in Brain Metastases from Colorectal Cancer and Corresponding Primary Tumors: A Case Cohort Series.Breast cancer brain metastases: new directions in systemic therapyNearly Complete Response of Brain Metastases from HER2 Overexpressing Breast Cancer with Lapatinib and Capecitabine after Whole Brain Irradiation.Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancerCancer and the metastatic substrate.Breast cancer brain metastases: a review of the literature and a current multidisciplinary management guideline.Emerging drugs in metastatic breast cancer: an update.Lapatinib plus capecitabine for brain metastases in patients with human epidermal growth factor receptor 2-positive advanced breast cancer: a review of the Anatolian Society of Medical Oncology (ASMO) experience.Optimal management of brain metastases from breast cancer. Issues and considerations.Treatment of brain metastases from HER-2-positive breast cancer: current status and new concepts.The role of systemic and targeted therapies in brain metastases.Brain metastases in breast cancer.Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study.Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions.Activity of T-DM1 in Her2-positive breast cancer brain metastases.Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis.Clinical features and outcome of leptomeningeal metastasis in patients with breast cancer: a single center experience.Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial.Biological subtypes and survival outcomes in breast cancer patients with brain metastases (study of the Anatolian Society of Medical Oncology).Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the AnatolianEfficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review.Pertuzumab, trastuzumab and docetaxel reduced the recurrence of brain metastasis from breast cancer: a case report.Current chemotherapeutic regimens for brain metastases treatment.
P2860
Q26775663-772D1CC3-2B9D-4FC4-AEFD-422E6CFD4956Q26777681-5B6B81CD-877C-4EE7-B180-6C09E07A8960Q26824799-BA34E226-EC43-48A0-AE9E-300F6C65523AQ33696559-CCDAED98-3090-405A-8A70-4AE10C6BE5F5Q33777436-F367D12B-51DB-4B92-ACB1-2F615B19E289Q34014740-C8F2B869-DAF8-47CF-B283-7E117CF7CDB7Q34285753-71CCA119-C150-4FCA-92CF-22FC63021734Q34762284-0640FE04-6D83-48C0-891C-FE9977E79A44Q35092651-B073D63A-A60E-4E6A-A67A-C2163CAE7839Q35608531-338086B0-F6AE-497D-B57A-3443DFA2AD05Q35653866-20E9B1CF-12B1-49FD-A7CA-AD8018B1AC4FQ35788631-42479524-B641-440E-9BF6-C0C891EA554BQ35835926-488E8102-28C8-4484-B14B-7E968A0CE9F6Q35967411-939BA8E1-91CC-421A-8517-3F3CEA9C9B7AQ36287951-EB7C1DEA-662B-498F-B18D-E228186C7EB8Q36371783-9B3730A1-30F2-45CC-8759-42FE34EF7382Q36372466-02A4D11A-3568-46F0-82D4-BE9C413DBCF2Q36655951-95310093-199A-4E2C-A772-6F3D5062AEA6Q36822500-BCDB33B7-FB24-4586-9745-D5D86FC7F17DQ37244367-5D0B9F34-9D64-4261-84AE-18686BE16032Q37355762-2A588FE4-27E8-4B30-BB8E-B960A88985D7Q37573461-01338C87-1361-46CD-868F-21952A97B898Q37698300-1B598610-819A-467D-9B53-9C051CF4AB7AQ37961957-40B04A54-44F4-4526-911E-DAE0C807F49DQ38064719-576FCEE3-4A60-4AB7-90A3-BDC04E699C41Q38067340-A23B1F65-15DB-4AF1-AF7A-5F6EB137A99CQ38155202-6C2408B3-3059-4B08-970C-F7769FA3E99FQ38168919-3E4813DB-E8CE-4C32-BC03-5BCBA9A1C5F3Q38168924-AD43CE71-C765-40E3-AF9D-B360EC1A670EQ38903136-0E40C47E-5D92-44E2-A508-EBB89A1E3BCFQ39652258-360E9217-B3F8-4A33-B322-084C707A4E69Q41455800-B1896429-3EE5-4D4A-8C1A-D3C1CB60C812Q41489396-BD07615F-51AE-4D55-A2D6-F3E528D9E885Q43589739-3C76AF9E-AB51-499C-AE85-E1546CA00D2BQ44134898-91343DEF-69EF-46CF-BFBD-D57E9823E849Q44625585-F790605F-1D40-48E7-84CC-7485DE2957A4Q47793228-FDA6376A-95F2-47D8-971B-883212976ED6Q47839509-00BD1D78-A3E3-421D-9B35-0A009BDC1BF1Q48106837-AD958494-5DF0-4140-A33F-F314ECF0882EQ48109517-FD8DDDCB-5DEE-409A-BD70-D8169450FA7E
P2860
Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Clinical outcome of patients w ...... th lapatinib and capecitabine.
@en
Clinical outcome of patients w ...... th lapatinib and capecitabine.
@nl
type
label
Clinical outcome of patients w ...... th lapatinib and capecitabine.
@en
Clinical outcome of patients w ...... th lapatinib and capecitabine.
@nl
prefLabel
Clinical outcome of patients w ...... th lapatinib and capecitabine.
@en
Clinical outcome of patients w ...... th lapatinib and capecitabine.
@nl
P2093
P2860
P50
P356
P1433
P1476
Clinical outcome of patients w ...... th lapatinib and capecitabine.
@en
P2093
F Cognetti
J Foglietta
M Mottolese
M Russillo
P2860
P304
P356
10.1093/ANNONC/MDQ434
P577
2010-08-19T00:00:00Z